Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2
mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Denosumab is a
monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Intervention

Denosumab, Salpingo-Oophorectomy

Condition

Ovarian Carcinoma

Investigators

Meghna S Trivedi, Judy E. Garber, Kevin Holcomb, Powel H. Brown, Nadir Arber, Meghna S. Trivedi, Eitan Friedman

See list of participating sites